| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Ziyuglycoside II targets various signaling pathways involved in inflammation, oxidative stress, and cancer. It may inhibit the activation of NF-κB and reduce the expression of pro-inflammatory cytokines. It may also induce apoptosis in cancer cells through the mitochondrial pathway and inhibit cell proliferation. The compound may modulate the PI3K/Akt and MAPK signaling pathways.
|
|---|---|
| ln Vitro |
In a dose-dependent manner, purpuroside II (10–60 μM; 24 h and 48 h) inhibits the growth of MDA-MB-435 cells. Purpurin II's half-life at 24 and 48 hours is 5.92 μM and 4.74 μM, respectively [1]. In MDA-MB-435 cells, purpuroside II (5–25 μM) causes G0/G1 and S phase arrest for a full day [1]. In MDA-MB-435 cells, ziyuglycoside II (5–25 μM; 24 h) markedly raised p53 and p21 expression. Ziyuglycoside II (5–25 μM; given to MDA-MB-435 cells for 24 hours). The simulation rate is affected by it[1].
In vitro, ziyuglycoside II has been shown to inhibit the growth of various cancer cell lines and induce apoptosis. It may also have anti-inflammatory effects by reducing the production of pro-inflammatory cytokines and inhibiting the activation of NF-κB. The compound has antioxidant activity by scavenging free radicals and reducing oxidative stress. |
| ln Vivo |
In vivo, ziyuglycoside II has been studied in animal models of inflammation and cancer. It may have anti-tumor effects in xenograft models and anti-inflammatory effects in models of inflammation. Its pharmacokinetics and bioavailability are areas of active research.
|
| Enzyme Assay |
For non-cellular enzyme assays, ziyuglycoside II can be tested for inhibition of enzymes such as COX-2, iNOS, and MMPs using standard enzyme activity assays. It can also be tested for antioxidant activity using DPPH, ABTS, or FRAP assays.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: MDA-MB-435 Cell Tested Concentrations: 10, 20, 30, 40, 50, 60 μM Incubation Duration: 24 hrs (hours) and 48 hrs (hours) Experimental Results: IC50 at 24 hrs (hours) and 48 hrs (hours) are 5.92 μM respectively and 4.74 μM. Cell cycle analysis[1] Cell Types: MDA-MB-435 Cell Tested Concentrations: 5, 10, 25 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of G0/G1 and S phase arrest. Apoptosis analysis [1] Cell Types: MDA-MB-435 Cell Tested Concentrations: 5, 10, 25 μM Incubation Duration: 24 hrs (hours) Experimental Results: Compared with the control, the cell apoptosis rate increased Dramatically. Western Blot Analysis[1] Cell Types: MDA-MB-435 Cell Tested Concentrations: 5, 10, 25 μM Incubation Duration: 24 hrs (hours) Experimental Results: Treatment resulted in increased expression of p53 and p21. For in vitro cell-based assays, cancer cell lines and inflammatory cell models are cultured and treated with ziyuglycoside II. Cell proliferation, apoptosis, and inflammatory marker expression are assessed using MTT assays, flow cytometry, ELISA, and Western blotting. |
| Animal Protocol |
For in vivo animal studies, ziyuglycoside II can be administered orally or intraperitoneally to animal models of disease. Inflammation models and cancer models can be used.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of ziyuglycoside II include solubility in DMSO and ethanol. It is a glycoside and may have poor oral bioavailability.
|
| Toxicity/Toxicokinetics |
As a natural product from Sanguisorba officinalis, ziyuglycoside II is generally considered safe at low doses.
|
| References |
|
| Additional Infomation |
Reports have indicated that Sanguisorba officinalis contains ziyuglycoside II, and relevant data is available for reference.
Ziyuglycoside II is a naturally occurring triterpenoid saponin from Sanguisorba officinalis. It has anti-inflammatory, antioxidant, and anticancer activities. It is a major bioactive constituent of Chinese burnet. |
| Molecular Formula |
C35H56O8
|
|---|---|
| Molecular Weight |
604.8144
|
| Exact Mass |
604.397
|
| CAS # |
35286-59-0
|
| PubChem CID |
71773126
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
716.2±60.0 °C at 760 mmHg
|
| Melting Point |
260-263℃
|
| Flash Point |
218.6±26.4 °C
|
| Vapour Pressure |
0.0±5.2 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
7.68
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
43
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O
|
| InChi Key |
MFIXLWYJTVEVGO-YHGWSDCJSA-N
|
| InChi Code |
InChI=1S/C35H56O8/c1-19-10-15-35(29(39)40)17-16-32(5)20(27(35)34(19,7)41)8-9-23-31(4)13-12-24(30(2,3)22(31)11-14-33(23,32)6)43-28-26(38)25(37)21(36)18-42-28/h8,19,21-28,36-38,41H,9-18H2,1-7H3,(H,39,40)/t19-,21+,22+,23-,24+,25+,26-,27-,28+,31+,32-,33-,34-,35+/m1/s1
|
| Chemical Name |
(1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~82.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.83 mg/mL (1.37 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.83 mg/mL (1.37 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (1.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6534 mL | 8.2671 mL | 16.5341 mL | |
| 5 mM | 0.3307 mL | 1.6534 mL | 3.3068 mL | |
| 10 mM | 0.1653 mL | 0.8267 mL | 1.6534 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
